UCB to Acquire Zogenix for up to $1.9B

Harmony Biosciences Acquires Zynerba Pharmaceuticals

August 14, 2023

Pharmaceuticals

Harmony Biosciences Holdings, Inc. agreed to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer of $1.1059 per share (approximately $60 million) plus one contingent value right (CVR) per share for up to $140 million of milestone-based payments (total potential consideration up to $200 million). The transaction, unanimously approved by both boards, is expected to close in Q4 2023 and will add Zynerba’s synthetic transdermal cannabidiol candidate Zygel and related rare neuropsychiatric programs to Harmony’s pipeline.

UCB Acquires Engage Therapeutics

June 5, 2020

Pharmaceuticals

Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Harmony Biosciences Acquires Epygenix Therapeutics

April 30, 2024

Biotechnology

Harmony Biosciences has acquired Epygenix Therapeutics, adding a late-stage rare epilepsy franchise (including EPX-100 and EPX-200) to its CNS pipeline. Harmony paid $35 million in cash with up to $130 million in development/regulatory milestones and up to $515 million in potential sales milestones to complete the transaction.

Bristol Myers Squibb Acquires RayzeBio for Approximately $4.1 Billion

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire radiopharmaceutical developer RayzeBio in an all-cash tender offer of $62.50 per share, valuing RayzeBio at approximately $4.1 billion (about $3.6 billion net of cash). The acquisition brings RayzeBio's actinium-based radiopharmaceutical platform, a Phase 3 lead program (RYZ101) and in-house radiopharmaceutical manufacturing capabilities into Bristol Myers Squibb's oncology franchise to accelerate development and commercialization of targeted radiopharmaceutical therapeutics.

Ginkgo Bioworks Acquires Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) will acquire Zymergen in an all‑stock transaction valuing Zymergen at about $300 million; Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share and will own ~5.25% of the combined company. The acquisition is intended to integrate Zymergen's automation, software, and data‑science capabilities and biological assets into Ginkgo's horizontal cell‑programming platform to expand capacity, capabilities, and efficiency across multiple end markets.